MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1626.0
(0.31%)
KRW 1626.0
(0.31%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 93.55 Billion KRW | 30.54% |
| 2022 | 71.66 Billion KRW | 5.05% |
| 2021 | 68.21 Billion KRW | -12.49% |
| 2020 | 77.95 Billion KRW | -5.77% |
| 2019 | 82.72 Billion KRW | 19.01% |
| 2018 | 69.51 Billion KRW | -3.09% |
| 2017 | 71.73 Billion KRW | 8.49% |
| 2016 | 66.12 Billion KRW | 1.49% |
| 2015 | 65.14 Billion KRW | 29.16% |
| 2014 | 50.43 Billion KRW | 7.36% |
| 2013 | 46.98 Billion KRW | -6.59% |
| 2012 | 50.29 Billion KRW | -13.15% |
| 2011 | 57.91 Billion KRW | 20.7% |
| 2010 | 47.98 Billion KRW | 3.01% |
| 2009 | 46.58 Billion KRW | 23.36% |
| 2008 | 37.75 Billion KRW | 51.74% |
| 2007 | 24.88 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 26.76 Billion KRW | 6.17% |
| 2024 Q2 | 26.5 Billion KRW | -0.96% |
| 2023 Q4 | 25.2 Billion KRW | 203.32% |
| 2023 FY | 93.55 Billion KRW | 30.54% |
| 2023 Q3 | -24.39 Billion KRW | -3.55% |
| 2023 Q2 | -23.55 Billion KRW | -212.16% |
| 2023 Q1 | 21 Billion KRW | 19.89% |
| 2022 Q2 | 19.59 Billion KRW | 19.31% |
| 2022 FY | 71.66 Billion KRW | 5.05% |
| 2022 Q1 | 16.42 Billion KRW | -25.78% |
| 2022 Q4 | 17.52 Billion KRW | -3.34% |
| 2022 Q3 | 18.12 Billion KRW | -7.5% |
| 2021 Q1 | 14.42 Billion KRW | -33.45% |
| 2021 Q2 | 14.92 Billion KRW | 3.51% |
| 2021 Q4 | 22.12 Billion KRW | 32.21% |
| 2021 Q3 | 16.73 Billion KRW | 12.12% |
| 2021 FY | 68.21 Billion KRW | -12.49% |
| 2020 FY | 77.95 Billion KRW | -5.77% |
| 2020 Q3 | 16.56 Billion KRW | -18.89% |
| 2020 Q4 | 21.67 Billion KRW | 30.85% |
| 2020 Q2 | 20.42 Billion KRW | 5.83% |
| 2020 Q1 | 19.29 Billion KRW | -22.61% |
| 2019 Q4 | 24.93 Billion KRW | 27.71% |
| 2019 FY | 82.72 Billion KRW | 19.01% |
| 2019 Q3 | 19.52 Billion KRW | -6.49% |
| 2019 Q2 | 20.87 Billion KRW | 20.1% |
| 2019 Q1 | 17.38 Billion KRW | 1.47% |
| 2018 Q3 | 18.06 Billion KRW | 2.48% |
| 2018 FY | 69.51 Billion KRW | -3.09% |
| 2018 Q1 | 16.67 Billion KRW | -8.29% |
| 2018 Q2 | 17.63 Billion KRW | 5.72% |
| 2018 Q4 | 17.13 Billion KRW | -5.19% |
| 2017 FY | 71.73 Billion KRW | 8.49% |
| 2017 Q2 | 19.43 Billion KRW | 15.45% |
| 2017 Q3 | 17.27 Billion KRW | -11.14% |
| 2017 Q1 | 16.83 Billion KRW | -3.44% |
| 2017 Q4 | 18.18 Billion KRW | 5.29% |
| 2016 Q1 | 15.4 Billion KRW | -24.65% |
| 2016 Q4 | 17.43 Billion KRW | -2.18% |
| 2016 Q3 | 17.82 Billion KRW | 13.3% |
| 2016 Q2 | 15.73 Billion KRW | 2.09% |
| 2016 FY | 66.12 Billion KRW | 1.49% |
| 2015 Q3 | 15.14 Billion KRW | 3.18% |
| 2015 Q1 | 14.87 Billion KRW | 7.44% |
| 2015 Q4 | 20.45 Billion KRW | 35.01% |
| 2015 Q2 | 14.67 Billion KRW | -1.29% |
| 2015 FY | 65.14 Billion KRW | 29.16% |
| 2014 Q3 | 12.94 Billion KRW | 13.59% |
| 2014 Q2 | 11.39 Billion KRW | -6.99% |
| 2014 Q4 | 13.84 Billion KRW | 6.92% |
| 2014 Q1 | 12.25 Billion KRW | 3.71% |
| 2014 FY | 50.43 Billion KRW | 7.36% |
| 2013 Q3 | 11.9 Billion KRW | 1.38% |
| 2013 FY | 46.98 Billion KRW | -6.59% |
| 2013 Q2 | 11.74 Billion KRW | 1.9% |
| 2013 Q4 | 11.81 Billion KRW | -0.75% |
| 2013 Q1 | 11.52 Billion KRW | -6.27% |
| 2012 Q1 | 13.05 Billion KRW | 0.0% |
| 2012 FY | 50.29 Billion KRW | -13.15% |
| 2012 Q2 | 12.16 Billion KRW | -6.84% |
| 2012 Q3 | 12.28 Billion KRW | 1.01% |
| 2012 Q4 | 12.29 Billion KRW | 0.08% |
| 2011 Q1 | 13.13 Billion KRW | 0.0% |
| 2011 Q3 | 13.95 Billion KRW | 6.04% |
| 2011 FY | 57.91 Billion KRW | 20.7% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 13.16 Billion KRW | 0.22% |
| 2010 Q1 | 11.48 Billion KRW | 0.0% |
| 2010 Q3 | 10.99 Billion KRW | 6.81% |
| 2010 FY | 47.98 Billion KRW | 3.01% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 10.29 Billion KRW | -10.34% |
| 2009 Q3 | 11.27 Billion KRW | -2.24% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 46.58 Billion KRW | 23.36% |
| 2009 Q1 | 10.65 Billion KRW | 13.04% |
| 2009 Q2 | 11.53 Billion KRW | 8.2% |
| 2008 Q3 | 10.92 Billion KRW | 12.36% |
| 2008 Q4 | 9.42 Billion KRW | -13.68% |
| 2008 Q2 | 9.72 Billion KRW | 0.0% |
| 2008 FY | 37.75 Billion KRW | 51.74% |
| 2007 FY | 24.88 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -97.976% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 68.606% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 46.281% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 64.15% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 66.401% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 18.456% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -35.164% |
| Yuhan Corporation | 489.94 Billion KRW | 80.906% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 69.523% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -123.864% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -29.963% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -133.569% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 25.984% |
| CKD Bio Corp. | 25.19 Billion KRW | -271.299% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -97.976% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -24.654% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -59.524% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 60.842% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 26.724% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -36.949% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -34.667% |
| HANDOK Inc. | 153.76 Billion KRW | 39.161% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -97.976% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 62.448% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 83.307% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 60.842% |
| Yuhan Corporation | 489.94 Billion KRW | 80.906% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 51.694% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 84.688% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 77.108% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -66.961% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 60.842% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 73.326% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -120.268% |
| JW Holdings Corporation | 301.25 Billion KRW | 68.946% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -42.281% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 46.519% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 26.724% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 57.859% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 20.863% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -40.854% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 43.341% |
| Boryung Corporation | 285.16 Billion KRW | 67.194% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -6.865% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 46.281% |
| JW Lifescience Corporation | 20.26 Billion KRW | -361.719% |